ClinicalTrials.gg
CompletedNCT02541383CassiopeiaUpdated Apr 13, 2025Results posted

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

A Phase 3 interventional study of Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) and Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab in Multiple Myeloma, sponsored by Intergroupe Francophone du Myelome. Completed at 107 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-13.

Sponsored by Intergroupe Francophone du Myelome · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,085
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
2nd of 267
1,085 · median 41
Started
2015
with 2 others
Phase 3
42 of 271
1 open now
Registered
210th of 271
by date

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 2nd largest by enrollment of the 267 interventional ones that give a count, is one of 3 that started in 2015, is one of 42 in phase 3, and was the 210th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free survival after daratumumab maintenance therapy in transplant eligible participants with previously untreated Multiple Myeloma.

Read the detailed description

This is a randomized, open-label (identity of assigned treatment will be known to participants and study staff), 2-arm (2 treatment groups), multicenter study of daratumumab in participants diagnosed with previously untreated Multiple Myeloma who are eligible for high dose chemotherapy and autologous stem cell transplantation (transplantation of own bone marrow). Participants will be randomized (assigned by chance) to one of 2 treatment groups to either receive daratumumab plus bortezomib, thalidomide and dexamethasone or bortezomib, thalidomide and dexamethasone for induction (before transplantation) and consolidation (after transplantation) treatment. All responders will then be re-randomized (assigned by chance) to one of 2 treatment groups to receive maintenance treatment with daratumumab only or observation (no treatment). The study will include a 28-Day Screening Phase, a Treatment Phase of 6 treatment cycles (each cycle is 4 weeks in duration for total period of 30 weeks), and a Follow up Phase of 2 years. The total duration for each participant in the study will be approximately 138 weeks. The end of the study will occur approximately 5 years after the last participant is randomized in the second phase of the study. Disease assessments will be performed every 4 weeks in the first phase of the study and then every 8 weeks in the second phase of the study. Safety will be monitored throughout the study.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Untreated Multiple Myeloma
  • daratumumab
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of previously untreated multiple myeloma (MM)
  • Have a confirmed diagnosis and eligible for high dose chemotherapy and stem cell transplantation, and an (ECOG) performance status score of 0,1 or 2

Exclusion criteria

Exclusion Criteria:

  • previous treatment for Multiple Myeloma
  • Primary amyloidosis, Plasma Cell Leukemia or Smoldering Multiple Myeloma
  • Prior or concurrent exposure to systemic therapy or SCT (Stem Cell Transplantation) for any plasma cell dyscrasia, with the exception of an emergency use of a short course (equivalent of dexamethasone 40 mg/day for a maximum 4 days) of before treatment, or received an drug or used an invasive investigational medical device within 4 weeks before Cycle 1, Day 1
  • history of (other than Multiple Myeloma) within 10 years before the date of randomization, except for the following if treated and not active: basal cell or nonmetastatic squamous cell carcinoma of the skin, cervical carcinoma in situ, ductal carcinoma in situ of breast, or International Federation of Gynecology and Obstetrics (FIGO) Stage 1 carcinoma of the cervix
  • known (COPD) or moderate to severe asthma
  • any concurrent medical or psychiatric condition or disease (eg, disease, active systemic disease, myelodysplasia) that is likely to interfere with the study procedures or results, or that in the opinion of the investigator, would constitute a hazard for participating in this study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,085 participants (actual)

Study arms

  • Other
    Arm A Part 1

    Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)

    Drug: Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)

  • Experimental
    Arm B Part 1

    Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) plus daratumumab

    Drug: Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab

  • No intervention
    Arm A Part 2

    Observation

  • Experimental
    Arm B Part 2

    daratumumab

    Drug: Daratumumab

Interventions

  • DrugBortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)

    Drug page: Bortezomib

    Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation

    Also known as: Arm A Part 1

  • DrugBortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab

    Drug pages: Bortezomib · Thalidomide · Dexamethasone · Daratumumab

    Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation

    Also known as: Arm B Part 1

  • Daratumumab 16mg/kg every 8 weeks for 2 years

    Also known as: Arm B Part 2

06

What researchers measure

Primary outcomes

  1. Post-Consolidation Stringent Complete Response (sCR) Rate

    Post-consolidation sCR rate is defined as the percentage of ITT subjects who achieved or maintained sCR status within 30 days of Day 100 post Autologous Stem Cell Transplant (ASCT). The sCR status is assessed using the computerized algorithm according to IMWG response criteria, and must be achieved on or prior to start of subsequent therapies. Subjects must not die or progress by Day 100 post ASCT. According to the IMWG consensus recommendations for multiple myeloma treatment response criteria from 2006, the stringent complete response (sCR) was defined by a negative immunofixation on the serum and urine, and a disappearance of any soft tissue plasmacytomas, and \< 5% plasma cells in bone marrow, plus normal free-light chain ratio and the absence of clonal bone marrow plasma cells by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.

    Time frame: At day 100 post Autologous Stem Cell Transplant (ASCT), up to 114 days post ASCT

  2. Progression Free Survival (PFS) Post Completion of Maintenance Therapy

    Progression Free Survival (PFS) post completion of maintenance therapy is defined as the duration from the date of second randomization to either progressive disease (according to the IMWG criteria specified in the protocol), or death, whichever occurs first (=all these considered as events) at the completion of Maintenance therapy.

    Time frame: From the date of second randomization to either progressive disease or death which ever occurred first, with a median follow-up time of 35.4 months (cut-off for analysis was 26 months after the last rando 2 date).

Secondary outcomes

  1. Progression Free Survival (PFS) From First Randomization up to the End of the Study

    Progression Free Survival (PFS) is defined as the duration from the date of first randomization to either progressive disease (according to the IMWG criteria specified in the protocol), or death, whichever occurs first (=all these considered as events) at the end of the study

    Time frame: From the date of first randomization to either progressive disease or death which ever occurred first, with a median follow-up time of 80.1 months at the end of the study

07

Results

Posted Apr 13, 2025

Participant flow

Participant flow — Overall Study
MilestoneVTd OnlyDVTd Only * Arm/Group Title: Characters Remaining: 91VTd-OBSVTd-DARADVTd-OBSDVTd-DARA
Started11485215213229229
Completed5338165170205204
Not completed614750432425
Withdrew: Death503748412125
Withdrew: Lost to follow-up531130
Withdrew: Consent withdrawn561100
Withdrew: Sponsor's decision110000

Outcome measures

PrimaryPost-Consolidation Stringent Complete Response (sCR) Rate

Post-consolidation sCR rate is defined as the percentage of ITT subjects who achieved or maintained sCR status within 30 days of Day 100 post Autologous Stem Cell Transplant (ASCT). The sCR status is assessed using the computerized algorithm according to IMWG response criteria, and must be achieved on or prior to start of subsequent therapies. Subjects must not die or progress by Day 100 post ASCT. According to the IMWG consensus recommendations for multiple myeloma treatment response criteria from 2006, the stringent complete response (sCR) was defined by a negative immunofixation on the serum and urine, and a disappearance of any soft tissue plasmacytomas, and \< 5% plasma cells in bone marrow, plus normal free-light chain ratio and the absence of clonal bone marrow plasma cells by immunohistochemistry, immunofluorescence or 2- to 4-color flow cytometry.

Time frame:
At day 100 post Autologous Stem Cell Transplant (ASCT), up to 114 days post ASCT
Reported as:
Count of participants · Participants
Post-Consolidation Stringent Complete Response (sCR) Rate
ParticipantsArm A Part 1Arm B Part 1
Post-Consolidation Stringent Complete Response (sCR) Rate110157
Statistical analysis
  • Arm A Part 1 vs Arm B Part 1 · Cochran-Mantel-Haenszel · p = 0.0010 · Odds ratio (or): 1.6 · 95% CI 1.21 to 2.12
PrimaryProgression Free Survival (PFS) Post Completion of Maintenance Therapy

Progression Free Survival (PFS) post completion of maintenance therapy is defined as the duration from the date of second randomization to either progressive disease (according to the IMWG criteria specified in the protocol), or death, whichever occurs first (=all these considered as events) at the completion of Maintenance therapy.

Time frame:
From the date of second randomization to either progressive disease or death which ever occurred first, with a median follow-up time of 35.4 months (cut-off for analysis was 26 months after the last rando 2 date).
Reported as:
Median · Months
Progression Free Survival (PFS) Post Completion of Maintenance Therapy
MonthsArm A Part 2Arm B Part 2
Progression Free Survival (PFS) Post Completion of Maintenance Therapy46.7 (40.0 to NA)NA (NA to NA)
Statistical analysis
  • Arm A Part 2 vs Arm B Part 2 · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.53 · 95% CI 0.42 to 0.68
SecondaryProgression Free Survival (PFS) From First Randomization up to the End of the Study

Progression Free Survival (PFS) is defined as the duration from the date of first randomization to either progressive disease (according to the IMWG criteria specified in the protocol), or death, whichever occurs first (=all these considered as events) at the end of the study

Time frame:
From the date of first randomization to either progressive disease or death which ever occurred first, with a median follow-up time of 80.1 months at the end of the study
Reported as:
Median · Months
Progression Free Survival (PFS) From First Randomization up to the End of the Study
MonthsArm A - Part 1 up to End of StudyArm B - Part 1 up to End of Study
Progression Free Survival (PFS) From First Randomization up to the End of the Study52.8 (47.5 to 58.7)83.7 (70.2 to NA)
Statistical analysis
  • Arm A - Part 1 up to End of Study vs Arm B - Part 1 up to End of Study · Log Rank · p = <0.0001 · Hazard ratio (hr): 0.61 · 95% CI 0.52 to 0.72

Adverse events

Collected over AEs that started during the treatment until 30 days after the last dose of study treatment, approximately 59 months, except for secondary malignancies and deaths followed until the end of the study.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
VTd - Part 1139/542 (25.6%)261/538 (48.5%)529/538 (98.3%)
DVTd - Part 183/543 (15.3%)264/536 (49.3%)534/536 (99.6%)
VTd-OBS - Part 248/215 (22.3%)35/215 (16.3%)170/215 (79.1%)
VTd-DARA - Part 241/211 (19.4%)58/211 (27.5%)194/211 (91.9%)
DVTd-OBS - Part 221/229 (9.2%)50/229 (21.8%)198/229 (86.5%)
DVTd-DARA - Part 225/229 (10.9%)43/229 (18.8%)205/229 (89.5%)
Most frequent serious events
Showing 10 of 379
Most frequent serious events
EventVTd - Part 1DVTd - Part 1VTd-OBS - Part 2VTd-DARA - Part 2DVTd-OBS - Part 2DVTd-DARA - Part 2
NeutropeniaBlood and lymphatic system disorders8/53822/5360/2150/2110/2290/229
PyrexiaGeneral disorders22/53815/5360/2150/2110/2292/229
PneumoniaInfections and infestations9/53821/5362/2154/2114/2297/229
Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders20/5388/5360/2150/2110/2291/229
Febrile NeutropeniaBlood and lymphatic system disorders16/53812/5360/2151/2110/2290/229
Peripheral Sensory NeuropathyNervous system disorders16/53811/5360/2150/2110/2290/229
ThrombocytopeniaBlood and lymphatic system disorders4/53812/5361/2150/2110/2290/229
Febrile Bone Marrow AplasiaBlood and lymphatic system disorders12/5387/5360/2150/2110/2290/229
SepsisInfections and infestations11/5387/5361/2150/2110/2291/229
Lung DisorderRespiratory, thoracic and mediastinal disorders6/53810/5360/2150/2110/2290/229
Most frequent other events
Showing 10 of 61
Most frequent other events
EventVTd - Part 1DVTd - Part 1VTd-OBS - Part 2VTd-DARA - Part 2DVTd-OBS - Part 2DVTd-DARA - Part 2
Peripheral Sensory NeuropathyNervous system disorders340/538325/53624/21531/21127/22939/229
ConstipationGastrointestinal disorders255/538271/5362/21510/2116/2297/229
BronchitisInfections and infestations79/538107/53671/21577/21163/22993/229
AstheniaGeneral disorders159/538176/53627/21535/21126/22926/229
Oedema PeripheralGeneral disorders154/538166/5368/2159/2119/22913/229
NauseaGastrointestinal disorders129/538159/5362/21533/2114/22910/229
NeutropeniaBlood and lymphatic system disorders83/538149/5366/2157/2114/2295/229
PyrexiaGeneral disorders104/538133/5367/21520/21117/22918/229
ParaesthesiaNervous system disorders114/538127/5364/21521/21110/22915/229
ThrombocytopeniaBlood and lymphatic system disorders72/538109/5364/2157/2114/22910/229

Baseline characteristics

Age, Continuous
Age, Continuous(years)VTd OnlyDVTd OnlyVTd-OBSVTd-DARADVTd-OBSDVTd-DARATotal
Mean57.7 ± 6.3657.8 ± 7.556 ± 6.9656.3 ± 7.3856.8 ± 6.8356.4 ± 6.7956.6 ± 6.98
Sex: Female, Male
Sex: Female, Male(Participants)VTd OnlyDVTd OnlyVTd-OBSVTd-DARADVTd-OBSDVTd-DARATotal
Female423794879694450
Male7248121126133135635
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)VTd OnlyDVTd OnlyVTd-OBSVTd-DARADVTd-OBSDVTd-DARATotal
Count of participants——————0
Region of Enrollment
Region of Enrollment(participants)VTd OnlyDVTd OnlyVTd-OBSVTd-DARADVTd-OBSDVTd-DARATotal
BELGIUM1551118231789
FRANCE7064191169177183854
NETHERLANDS291613262929142
Baseline ISS Stage
Baseline ISS Stage(participants)VTd OnlyDVTd OnlyVTd-OBSVTd-DARADVTd-OBSDVTd-DARATotal
I472588938396432
II5241968511896488
III151931352837165
Baseline Type of Myeloma
Baseline Type of Myeloma(participants)VTd OnlyDVTd OnlyVTd-OBSVTd-DARADVTd-OBSDVTd-DARATotal
Biclonal121085531
IgA151446433637191
IgD31372218
IgG7954126128159138684
IgM0011013
Kappa1191718172799
Lambda3510781750
Negative immunofixation2021229
Time since initial diagnosis to randomization (months)
Time since initial diagnosis to randomization (months)(months)VTd OnlyDVTd OnlyVTd-OBSVTd-DARADVTd-OBSDVTd-DARATotal
Mean1.6 ± 2.651.3 ± 0.961.2 ± 0.861.2 ± 0.871.2 ± 1.081.2 ± 0.951.2 ± 1.25
Presence of diffuse myeloma-related osteopenia
Presence of diffuse myeloma-related osteopenia(participants)VTd OnlyDVTd OnlyVTd-OBSVTd-DARADVTd-OBSDVTd-DARATotal
No10076197194203208978
Yes14918172519102
Missing0002125

2 further baseline measures are reported on the registry.

08

Study locations

107 sites
  • BE-Antwerp-ZNA Stuivenberg
    Antwerp, Belgium
  • AZ St Jan Brugge Oostende AV
    Brugge, Belgium
  • Institut Jules Bordet
    Bruxelles, Belgium
  • UCL Saint-Luc
    Bruxelles, Belgium
  • UZ Brussel
    Bruxelles, Belgium
  • GHDC
    Charleroi, Belgium
  • UZ Gent
    Gent, Belgium
  • CH Jolimont
    La Louviere, Belgium
  • University Hospital Leuven
    Leuven, Belgium
  • Domaine Universitaire du Sart Tilman
    Liege, Belgium
  • AZ Delta
    Roeselare, Belgium
  • AZ Turnhout
    Turnhout, Belgium
  • UCL Mont-Godinne
    Yvoir, Belgium
  • CHU Amiens Sud
    AMIENS Cedex 1, France
  • CHRU-Hôpital du Bocage
    ANGERS Cedex 1, France
  • Centre Hospitalier d'Argenteuil Victor Dupouy
    Argenteuil, France
  • Centre Hospitalier H.Duffaut
    AVIGNON Cedex 9, France
  • Centre hospitalier de la Côte Basque
    Bayonne, France
  • Hôpital Jean Minjoz
    BESANCON Cedex, France
  • Hôpital Avicenne
    BOBIGNY Cedex, France
  • Polyclinique Bordeaux Nord Acquitaine
    Bordeaux, France
  • Hôpital de Fleyriat
    BOURG EN BRESSE Cedex, France
  • CHRU Brest - Hôpital A. Morvan
    BREST Cedex, France
  • CHU Caen - Côte de Nacre
    CAEN Cedex, France
  • Clinique du Parc
    Castelnau-le-lez, France
  • CH René Dubos
    Cergy-pontoise, France
  • Hôpital Privé Sévigné
    Cesson-Sévigné, France
  • Centre Hospitalier William Morey
    Chalon-sur-Saône, 71100, France
  • CH Chambéry
    Chambery, France
  • Hôpital d'Instruction des Armées Percy
    CLAMART Cedex, France
  • CHU d'Estaing
    Clermont-ferrand, France
  • Centre Hospitalier Sud Francilien
    CORBEIL-ESSONNES Cedex, France
  • CHU Henri Mondor
    Creteil, France
  • CHRU Dijon - Hôpital des Enfants
    Dijon, France
  • Centre Hospitalier Général
    Dunkerque, France
  • CHRU Hôpital A. Michallon
    GRENOBLE Cedex 9, France
  • CHD Vendée
    LA ROCHE SUR YON Cedex 9, France
  • CHV André Mignot - Université de Versailles
    Le Chesnay, France
  • CH de Chartres - Hôpital Louis Pasteur
    Le Coudray, France
  • Centre Hospitalier
    LE MANS Cedex, France
  • Clinique Victor Hugo
    Le Mans, France
  • CHRU Hôpital Claude Huriez
    LILLE Cedex, France
  • GH de l'Institut Catholique Saint Vincent
    Lille, France
  • Centre Hospitalier Universitaire (CHU) de Limoges
    Limoges, France
  • Hôpital du Scorff
    Lorient, France
  • Centre Léon Bérard
    Lyon, France
  • Institut Paoli Calmettes
    MARSEILLE Cedex, France
  • CH Meaux
    Meaux, France
  • Hôpital de Mercy (CHR Metz-Thionville)
    METZ Cedex 1, France
  • Hopital Saint Eloi - CHU Montpellier
    MONTPELLIER Cedex, France
  • Hôpital E. Muller
    Mulhouse, France
  • CHRU Hôtel Dieu
    Nantes Cedex 1, France
  • Centre Catherine de Sienne
    Nantes, 44202, France
  • Clinique de l'Archet
    NICE Cedex 3, France
  • CHU Carémeau
    NIMES Cedex 9, France
  • CH La Source
    Orleans Cedex 2, France
  • Hôpital Saint Louis
    PARIS Cedex 10, France
  • CHU Hôpital Saint Antoine
    PARIS Cedex 12, France
  • Hôpital Cochin
    Paris, France
  • Hôpital Necker
    Paris, France
  • Institut Curie
    Paris, France
  • La Pitié
    Paris, France
  • Centre Hospitalier de Perigueux
    Perigueux, France
  • CH Saint Jean
    Perpignan, France
  • CHRU - Hôpital du Haut Lévêque - Centre François Magendie
    Pessac, France
  • Centre Hospitalier Lyon Sud
    PIERRE-BENITE Cedex, France
  • CHU Poitiers - Pôle régional de Cancérologie
    Poitiers, France
  • Ch Annecy Genevois
    PRINGY Cedex, France
  • Hôpital Robert Debré
    REIMS Cedex, France
  • CHRU Hôpital de Pontchaillou
    RENNES Cedex 9, France
  • Centre Henri Becquerel
    ROUEN Cedex 1, France
  • Institut de Cancérologie Lucien Neuwirth
    Saint Priest-en-jarez, France
  • Centre Hospitalier
    SAINT QUENTIN Cedex, France
  • Centre Hospitalier Yves Le Foll
    Saint-brieuc, France
  • CHU Strasbourg
    Strasbourg, France
  • Strasbourg Oncologie Médicale
    Strasbourg, France
  • Pôle IUCT Oncopole CHU
    TOULOUSE Cedex 9, France
  • CHRU Hôpital Bretonneau
    TOURS Cedex, France
  • CHRU Hôpitaux de Brabois
    VANDOEUVRE LES NANCY Cedex, France
  • CHBA
    VANNES Cedex, France
  • MC Alkmaar
    Alkmaar, Netherlands
  • Meander MC
    Amersfoort, Netherlands
  • AMC
    Amsterdam, Netherlands
  • OLVG
    Amsterdam, Netherlands
  • Vumc
    Amsterdam, Netherlands
  • Ziekenhuis Rijnstate
    Arnhem, Netherlands
  • Amphia Hospital Breda
    Breda, Netherlands
  • RdGG
    Delft, Netherlands
  • Haga zkh
    Den Haag, 2545 CH, Netherlands
  • Deventer zkh
    Deventer, Netherlands
  • Albert Schweitzer zkh
    Dordrecht, Netherlands
  • Maxima MC
    Eindhoven, Netherlands
  • Medisch Spectrum Twente
    Enschede, Netherlands
  • UMCG
    Groningen, Netherlands
  • Atrium MC/Zuyderland MC
    Heerlen, Netherlands
  • Tergooiziekenhuizen, location Hilversum
    Hilversum, 1201 DA, Netherlands
  • Spaarne Gasthuis
    Hoofddorp, Netherlands
  • MC Leeuwarden
    Leeuwarden, Netherlands
  • LUMC
    Leiden, Netherlands
  • MUMC
    Maastricht, Netherlands

Showing the first 100 of 107 sites across 3 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Moreau P, Attal M, Hulin C, Arnulf B, Belhadj K, Benboubker L, Bene MC, Broijl A, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Garderet L, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Lenain P, Macro M, Mathiot C, Orsini-Piocelle F, Perrot A, Stoppa AM, van de Donk NW, Wuilleme S, Zweegman S, Kolb B, Touzeau C, Roussel M, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Fermand JP, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Zhuang S, Chiu C, Pei L, de Boer C, Smith E, Deraedt W, Kampfenkel T, Schecter J, Vermeulen J, Avet-Loiseau H, Sonneveld P. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study. Lancet. 2019 Jul 6;394(10192):29-38. doi: 10.1016/S0140-6736(19)31240-1. Epub 2019 Jun 3. PubMed 31171419 ↗
  • Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Bene MC, Zweegman S, Caillon H, Caillot D, Corre J, Delforge M, Dejoie T, Doyen C, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Stoppa AM, van de Donk NWCJ, Wuilleme S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Ahmadi T, Krevvata M, Zhang K, de Boer C, Vara S, Kampfenkel T, Vanquickelberghe V, Vermeulen J, Avet-Loiseau H, Sonneveld P. Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021 Oct;22(10):1378-1390. doi: 10.1016/S1470-2045(21)00428-9. Epub 2021 Sep 13. PubMed 34529931 ↗
  • Moreau P, Hulin C, Perrot A, Arnulf B, Belhadj K, Benboubker L, Zweegman S, Caillon H, Caillot D, Avet-Loiseau H, Delforge M, Dejoie T, Facon T, Sonntag C, Fontan J, Mohty M, Jie KS, Karlin L, Kuhnowski F, Lambert J, Leleu X, Macro M, Orsini-Piocelle F, Roussel M, Schiano de Colella JM, van de Donk NW, Wuilleme S, Broijl A, Touzeau C, Tiab M, Marolleau JP, Meuleman N, Vekemans MC, Westerman M, Klein SK, Levin MD, Offner F, Escoffre-Barbe M, Eveillard JR, Garidi R, Hua W, Wang J, Tuozzo A, de Boer C, Rowe M, Vanquickelberghe V, Carson R, Vermeulen J, Corre J, Sonneveld P; Intergroupe Francophone du Myelome, the Dutch-Belgian Cooperative Trial Group for Hematology Oncology and the CASSIOPEIA Investigators. Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial. Lancet Oncol. 2024 Aug;25(8):1003-1014. doi: 10.1016/S1470-2045(24)00282-1. Epub 2024 Jun 15. PubMed 38889735 ↗
  • Alberge JB, Kraeber-Bodere F, Jamet B, Touzeau C, Caillon H, Wuilleme S, Bene MC, Kampfenkel T, Sonneveld P, van Duin M, Avet-Loiseau H, Corre J, Magrangeas F, Carlier T, Bodet-Milin C, Cherel M, Moreau P, Minvielle S, Bailly C. Molecular Signature of 18F-FDG PET Biomarkers in Newly Diagnosed Multiple Myeloma Patients: A Genome-Wide Transcriptome Analysis from the CASSIOPET Study. J Nucl Med. 2022 Jul;63(7):1008-1013. doi: 10.2967/jnumed.121.262884. Epub 2022 Jan 27. PubMed 35086897 ↗
  • Hulin C, Offner F, Moreau P, Roussel M, Belhadj K, Benboubker L, Caillot D, Facon T, Garderet L, Kuhnowski F, Stoppa AM, Kolb B, Tiab M, Jie KS, Westerman M, Lambert J, Pei L, Vanquickelberghe V, De Boer C, Vermeulen J, Kampfenkel T, Sonneveld P, Van de Donk NWCJ. Stem cell yield and transplantation in transplant-eligible newly diagnosed multiple myeloma patients receiving daratumumab + bortezomib/thalidomide/dexamethasone in the phase 3 CASSIOPEIA study. Haematologica. 2021 Aug 1;106(8):2257-2260. doi: 10.3324/haematol.2020.261842. No abstract available. PubMed 33657786 ↗
  • Roussel M, Moreau P, Hebraud B, Laribi K, Jaccard A, Dib M, Slama B, Dorvaux V, Royer B, Frenzel L, Zweegman S, Klein SK, Broijl A, Jie KS, Wang J, Vanquickelberghe V, de Boer C, Kampfenkel T, Gries KS, Fastenau J, Sonneveld P. Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial. Lancet Haematol. 2020 Dec;7(12):e874-e883. doi: 10.1016/S2352-3026(20)30356-2. PubMed 33242444 ↗

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Aug 2020, 59 months.

Results were first posted in Apr 2025, 4 years 7 months after primary completion.

Of 71 non-industry phase 3 interventional studies under Multiple Myeloma, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 108. This study's 59 months is below that.

Counting every sponsor, half of 178 studies reached it within 55 months; a quarter within 34 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2015
First posted
Sep 4, 2015
StartActual
Sep 2015
Primary completionActual
Aug 27, 2020
CompletionActual
Sep 1, 2023
Results first posted
Apr 13, 2025
Last update
Apr 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02541383
Lead sponsor
Intergroupe Francophone du Myelome
Collaborators
HOVON - Dutch Haemato-Oncology Association, Janssen Research & Development, LLC
Responsible party
Sponsor
First posted
Sep 4, 2015
Start date
Sep 2015
Primary completion
Aug 27, 2020
Completion
Sep 1, 2023
Results posted
Apr 13, 2025
Last update
Apr 13, 2025

Study contacts

Philippe Moreau, Pr
principal investigator · CHU Nantes, France

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bortezomib · Thalidomide · Dexamethasone · Daratumumab

Start the discussion